| Management target | Revenue 60.0% FY27 |
|---|
| Revenue growth | 16% in FY26; 60%+ target for FY27. |
|---|---|
| Margins | EBITDA margin improved from 25.35% to 28.45% YoY. |
| Order book | ₹47.46 Cr order from a PSU pending execution. |
| Demand visibility | Strong; secured ₹47.46 Cr PSU order recently. |
| Management confidence | High; citing successful IPO and growth strategy execution. |
Growth
FY26 Revenue reached ₹52.51 Cr (+16% YoY); PAT grew 23% to ₹8.75 Cr.
Outlook
Guided at least 60% revenue growth for FY27; investing ₹30.18 Cr in fully automated Noida facility by Oct-26.
Risks
Lengthy CDSCO regulatory processes (9-12 months per product) create significant entry barriers and timeline dependencies.
Investor Presentation filed with NSE, NSE: AVIENCE. Summary written with AI assistance from the document.
Avience Biomedicals Ltd: key numbers
- Share price
- ₹342.05
- Market cap
- ₹187.6 Cr
- Revenue (annual)
- ₹52.51 Cr
- Net profit (annual)
- ₹8.75 Cr
- P/E (TTM)
- 21.4×Sector 57.8×
- Promoter holding
- 64.59%
- FII holding
- 3.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Avience Biomedicals Ltd
All →Avience Biomedicals Annual General Meeting
Avience Biomedicals Limited has scheduled its 7th Annual General Meeting for September 30, 2026. The company also announced book closure dates for the AGM.
Avience Biomedicals Other Announcement
The company informed shareholders about accessing the 7th AGM Notice and Annual Report via web links and requested KYC updates for those with unregistered emails.
Avience Biomedicals Annual General Meeting
Avience Biomedicals filed notice of its 7th AGM, set for September 30, 2026, with its FY 2025-26 Annual Report. No monetary transaction is disclosed.
Avience Biomedicals H2 FY26 Results: Net Profit ₹4.2 Cr, Down 2.3% YoY
Avience Biomedicals Ltd reported revenue from operations of ₹25.7 Cr (+4.9% YoY) and net profit of ₹4.2 Cr (-2.3% YoY) for H2 FY26.
- Key figure
- Net profit ₹4.2 Cr · -2.3% YoY
Avience Biomedicals Earnings Call Transcript: Key Takeaways
Avience Biomedicals reported FY26 revenue of ₹52.51 Cr (up 16%) with EBITDA margins improving to 28.45%. Strategy focuses on shifting from trading to in-house manufacturing and scaling exports.
- Call
- Guides 60% growth